| |
NGS is unlocking new possibilities in discovery and diagnostics, but few solutions can keep up with its needs. Access our toolkit to discover how out-of-the-box NGS empowers innovators to hit the ground running. Learn more.
|
|
Today's Big NewsJul 13, 2023 |
|
Sciensus offers the infrastructure, regulatory expertise and experience to navigate the complexities of international distribution and get your rare drugs to hard-to-reach patients. Learn more.
|
|
| By Max Bayer Rupert Vessey will join Flagship Pioneering as the venture firm's first chief scientist. He joins after leading research and early development at Bristol Myers Squibb for four years. |
|
|
|
By Nick Paul Taylor Roche is pushing deeper into synthetic lethality. One year after paying $125 million to join the ATR race, the Swiss drug developer has secured an exclusive global license to KSQ Therapeutics’ early-phase USP1 inhibitor. |
By Annalee Armstrong Sigilon Therapeutics really wanted to be bought by Eli Lilly. That much is clear in SEC documents filed Thursday that provide a peek behind the scenes at the deal-making process. |
Sponsored by Clinical Enrollment Using behavioral data science and social algorithms, this boutique biotech agency creates therapeutic-specific and patient-centric content to bypass traditional channels and speak directly to patients. |
By James Waldron BioGeneration Ventures has closed its largest fund to date, drawing in 150 million euros ($168 million) with the help of some returning Big Pharmas. |
Sponsored by OneStudyTeam Hear why sponsors should equip sites with technology that makes securely capturing pre-screening, recruitment, and enrollment data easier. |
By Nick Paul Taylor First Wave BioPharma’s bid to challenge AbbVie for a gastrointestinal market has suffered a setback, with the biotech telling investors “it is likely the primary efficacy endpoint was not achieved.” |
By Max Bayer Sirona Biochem's efforts to find a partner for its diabetes med are falling flat, the company said, in part because it can't get a hold of clinical trial data from an external partner. The company now says its less confident it will secure a new collaborator. |
By Helen Floersh Little is known about the prevalence of Alzheimer's disease in Samoan and other Asian American-Pacific Islander communities. Researchers like Justina Tavana, Ph.D., are hoping to change that. |
By James Waldron ObsEva has resecured the China rights to its pregnancy drug after Yuyuan BioScience allegedly failed to hit pre-agreed milestones on time. |
By Joseph Keenan Swiss pharma giant Novartis welcomed new collaborators to its Beacon of Hope initiative focused on expanding clinical trial inclusion and medical care for underserved patient populations. |
By Fraiser Kansteiner Nearly 50 years after norgestrel’s original green light, Perrigo’s oral contraceptive Opill has converted its prescription approval into an OTC nod. The FDA thumbs-up comes two months after the progestin-only tablet won unanimous backing at an FDA meeting of outside experts, paving the way for nonprescription use in patients of all ages. |
By Andrea Park Recursion claims that its AI platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several candidates already in clinical trials, the company is still making moves to strengthen its tech. |
By Anastassia Gliadkovskaya Mental health conditions are the leading cause of maternal mortality. Yet despite national guidance, addressing them remains complicated. |
By Andrea Park AccurKardia’s software relies on AI algorithms and other technologies to scan readouts collected by a variety of compatible ECG devices. |
By Kevin Dunleavy Five weeks after getting no response from the U.S. Department of Health and Human Services on his request for more information on the potential financial impact of Eisai and Biogen’s newly approved Alzheimer’s treatment Leqembi, Sen. Bernie Sanders (I-Vt.) has sent a follow-up letter to the HHS. The drug has been priced at $26,500 per patient per year. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
